Edition:
United States

Critical Outcome Technologies Inc (COT.V)

COT.V on TSX Venture Exchange

1.13CAD
1:38pm EDT
Change (% chg)

$-0.04 (-3.42%)
Prev Close
$1.17
Open
$1.17
Day's High
$1.17
Day's Low
$1.13
Volume
4,620
Avg. Vol
19,336
52-wk High
$6.40
52-wk Low
$1.01

Latest Key Developments (Source: Significant Developments)

CRITICAL OUTCOME TECHNOLOGIES DOSES FIRST PATIENT IN HNSCC ARM OF PHASE 1 TRIAL OF COTI-2
Wednesday, 11 Oct 2017 07:00am EDT 

Oct 11 (Reuters) - Critical Outcome Technologies Inc ::CRITICAL OUTCOME TECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL OF COTI-2 IN HEAD AND NECK SQUAMOUS CELL CARCINOMA.CRITICAL OUTCOME TECHNOLOGIES - ‍TOP-LINE DATA OF COTI-2 IN HEAD AND NECK SQUAMOUS CELL CARCINOMA ​EXPECTED IN 2018.CRITICAL OUTCOME TECHNOLOGIES INC - ‍REMAIN ON TRACK TO ANNOUNCE SECONDARY AND EXPLORATORY ENDPOINT DATA OF COTI-2​ BY YEAR-END.  Full Article

Critical Outcome Technologies Q1 loss per share C$0.02
Friday, 29 Sep 2017 05:58pm EDT 

Sept 29 (Reuters) - Critical Outcome Technologies Inc :Critical Outcome Technologies reports fiscal 2018 first quarter financial and operating results.Q1 loss per share C$0.02.  Full Article

Critical Outcome Technologies announces Q4 loss per share C$0.13
Monday, 28 Aug 2017 08:30am EDT 

Aug 28 (Reuters) - Critical Outcome Technologies Inc :Critical Outcome Technologies announces fourth quarter and full year 2017 financial results.Q4 loss per share C$0.13.Critical Outcome Technologies - Following completion of preclinical studies co expects to file an IND application for COTI-219 with the FDA​.‍IND filing for COTI-2 with FDA expected in early 2018.  Full Article

Critical Outcome Technologies completes phase 1 dose escalation portion of COTI-2 trial
Monday, 14 Aug 2017 08:00am EDT 

Aug 14 (Reuters) - Critical Outcome Technologies Inc :Critical Outcome Technologies completes phase 1 dose escalation portion of COTI-2 trial in gynecological malignancies.Has initiated an expansion arm of its phase 1 study in patients with head and neck squamous cell carcinoma​.Company expects top-line data from head and neck squamous cell carcinoma expansion arm in 2018 ​.  Full Article

Critical Outcome Technologies Q4 loss per share c$0.018
Wednesday, 3 Aug 2016 07:30am EDT 

Critical Outcome Technologies :Q4 loss per share c$0.018.  Full Article

Critical Outcome Tech appoints Alison Silva as new president
Wednesday, 15 Jun 2016 09:15am EDT 

Critical Outcome Technologies Inc : Appointment of alison silva as new president of company effective july 5, 2016 .Critical outcome technologies appoints experienced industry executive as new president.  Full Article

Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study
Monday, 6 Jun 2016 08:30am EDT 

Critical Outcome Technologies Inc :Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study.  Full Article

BRIEF-CRITICAL OUTCOME TECHNOLOGIES DOSES FIRST PATIENT IN HNSCC ARM OF PHASE 1 TRIAL OF COTI-2

* CRITICAL OUTCOME TECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL OF COTI-2 IN HEAD AND NECK SQUAMOUS CELL CARCINOMA